Advancing insights in critical COVID-19: unraveling lymphopenia through propensity score matching - Findings from the Multicenter LYMPH-COVID Study
Open Access
- 1 January 2024
- journal article
- research article
- Published by Associação de Medicina Intensiva Brasileira in Critical Care Science
- Vol. 36
Abstract
Objective To elucidate the impact of lymphopenia on critical COVID-19 patient outcomes. Methods We conducted a multicenter prospective cohort study across five hospitals in Portugal and Brazil from 2020 to 2021. The study included adult patients admitted to the intensive care unit with SARS-CoV-2 pneumonia. Patients were categorized into two groups based on their lymphocyte counts within 48 hours of intensive care unit admission: the Lymphopenia Group (lymphocyte serum count < 1 × 109/L) and the Nonlymphopenia Group. Multivariate logistic regression, propensity score matching, Kaplan‒Meier survival curve analysis and Cox proportional hazards regression analysis were used. Results A total of 912 patients were enrolled, with 191 (20.9%) in the Nonlymphopenia Group and 721 (79.1%) in the Lymphopenia Group. Lymphopenia patients displayed significantly elevated disease severity indices, including Sequential Organ Failure Assessment and Simplified Acute Physiology Score 3 scores, at intensive care unit admission (p = 0.001 and p < 0.001, respectively). Additionally, they presented heightened requirements for vasopressor support (p = 0.045) and prolonged intensive care unit and in-hospital stays (both p < 0.001). Multivariate logistic regression analysis after propensity score matching revealed a significant contribution of lymphopenia to mortality, with an odds ratio of 1,621 (95%CI: 1,275 - 2,048; p < 0.001). Interaction models revealed an increase of 8% in mortality for each decade of longevity in patients with concomitant lymphopenia. In the subanalysis utilizing three-group stratification, the Severe Lymphopenia Group had the highest mortality rate, not only in direct comparisons but also in Kaplan‒Meier survival analysis (log-rank test p = 0.0048). Conclusion Lymphopenia in COVID-19 patients is associated with increased disease severity and an increased risk of mortality, underscoring the need for prompt support for critically ill high-risk patients. These findings offer important insights into improving patient care strategies for COVID-19 patients.Keywords
This publication has 27 references indexed in Scilit:
- The putative mechanism of lymphopenia in COVID-19 patientsJournal of Molecular Cell Biology, 2022
- Lymphopenia in patients affected by SARS-CoV-2 infection is caused by margination of lymphocytes in large bowel: an [18F]FDG PET/CT studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2022
- Lymphopenia: A useful predictor of COVID-19 disease severity and mortalityPakistan Journal of Medical Sciences, 2021
- Neutrophils and lymphopenia, an unknown axis in severe COVID-19 diseasePLOS Pathogens, 2021
- Impact of age and gender on lymphocyte subset counts in patients with COVID‐19Cytometry Part A, 2021
- Lymphopenia and lung complications in patients with coronavirus disease‐2019 (COVID‐19): A retrospective study based on clinical dataJournal of Medical Virology, 2021
- Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromesThe Lancet Respiratory Medicine, 2020
- Lymphopenia during the COVID-19 infection: What it shows and what can be learnedImmunology Letters, 2020
- Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysisInternational Journal of Infectious Diseases, 2020
- COVID‐19 and the clinical hematology laboratoryInternational Journal of Laboratory Hematology, 2020